Cargando…

P1117: GLOFITAMAB PLUS R-CHOP OR POLATUZUMAB VEDOTIN-R-CHP IS DELIVERABLE AND YIELDS HIGH OVERALL RESPONSE IN PATIENTS <=65 YEARS OF AGE WITH HIGH-RISK DLBCL OR HGBL: INTERIM ANALYSIS OF THE COALITION STUDY

Detalles Bibliográficos
Autores principales: Minson, Adrian, Verner, Emma, Giri, Pratyush, Min Wong, Shu, Ratnasingam, Sumita, Butler, Jason, Janowski, Wojciech, Ku, Matthew, Cheah, Chan, Hertzberg, Mark, Herbert, Kirsten, Hamad, Nada, Yannakou, Costas, Neeson, Paul, Saghebi, Javad, Blombery, Piers, Robertson, Molly, Shong Lau, Lei, Xie, Jing, Seymour, John, Dickinson, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431134/
http://dx.doi.org/10.1097/01.HS9.0000971364.86087.32